Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose
(dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the
GeNOsyl® System compared to placebo.